PEMETREXED AND CARBOPLATIN VERSUS DOCETAXEL AND CARBOPLATIN AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED, NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0

作者：

Ganju, Vinod ^{[1
]}

Pereira, Jose ^{[2
]}

Kim, Joo-Hang ^{[3
]}

Magallanes, Manuel ^{[4
]}

Lee, Dae-Ho ^{[5
]}

Wang, Jie ^{[6
]}

Martinez, Luis ^{[7
]}

Barraclough, Helen

Van Kooten, Maximiliano

Orlando, Mauro

机构：

[1] Frankston Private Hosp, Peninsula Oncol Ctr, Frankston, Vic, Australia

[2] Inst Arnaldo Vieira De Carvalho, Oncopneumol Dept, Sao Paulo, Brazil

[3] Yonsei Canc Ctr, Seoul, South Korea

[4] Mil Hosp Mexico, Dept Med Oncol, Mexico City, DF, Mexico

[5] Univ Ulsan, Coll Med, Asan Med Ctr, Ulsan, South Korea

[6] Beijing Canc Hosp & Inst, Dept Thorac Oncol, Beijing, Peoples R China

[7] Natl Inst Resp Dis, Dept Oncol, Mexico City, DF, Mexico

来源：

关键词：

Pemetrexed; Docetaxel; Non-squamous nsmall cell lung cancer; Carboplatin;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S417 / S418

页数：2